Table 2.

Results of Primary and Secondary Analyses

Endpoint	Active	Placebo	Test statistic and p-value
Rhinovirus-associated illness# (%, 95% CI)	63 (56, 47; 66)	60 (50, 41; 59)	χ2=0•91, p=0•34
Duration of illness* (days, Median)	11•0	11•5	Z value=0•05 p=0•934
Number of subjects infected (%, 95% CI)	96 (86, 78; 92)	96 (80, 72; 87)	χ2=1•33
Viral titer (log. (95% CI))	1.28 (1.15; 1.41)	1.26 (1.13; 1.39)	F value= 0•28
Number of subjects virus positive (%, 95% CI)	87 (78, 69; 85)	83 (69, 60; 77)	χ2=0.82
Daily total symptom score, study days 1-5 (log. (95% CI))	1.12 (0.95; 1.28)	1.12 (0.96; 1.29)	Z value= -0•069
Daily total symptom score, study days 1-14 (log.)	0.76 (0.60; 0.93)	0.82 (0.63; 1.01)	Z value= -0•470

For endpoints analyzed with statistical tests, descriptive summaries are presented.

^#Primary endpoint

^⁎Duration of illness in subjects who met the protocol definition of a RV-associated illness